• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Drugs

  • Print
  • Share
  • E-mail

Alzheimer's Disease Regulatory Science Fellowship

 

FDA is supporting a new fellowshipdisclaimer icon launched by the Alzheimer’s Associationdisclaimer icon and the Reagan-Udall Foundation for the FDA (RUF)disclaimer icon. This fellowship is open to experienced physicians dedicated to treating and studying Alzheimer’s disease.
 
The fellow will work directly in the Center for Drug Evaluation and Research’s Division of Neurology Products to nurture current partnerships and identify new opportunities for collaboration with stakeholders in the Alzheimer’s disease community, including patient groups, academic researchers, and pharmaceutical manufacturers.
 
More than 5 million Americans are living with Alzheimer’s disease, the sixth leading cause of death in the U.S. Yet there are currently no approved therapies to prevent the disease or slow its progression. The growing prevalence of Alzheimer’s disease, along with the failure to produce effective therapies has led many in the community to rethink how Alzheimer’s treatments are developed and evaluated.
 
FDA, RUF, and the Alzheimer’s Association see this fellowship as a prime opportunity to reconsider the current landscape of Alzheimer’s drug development. The fellow will be tasked with exploring the utility of diagnostic tools, critical biomarkers, and novel clinical trial designs to advance the development of treatments for Alzheimer’s disease and other neurodegenerative disorders.
 
Applications will be reviewed on a rolling basis with a flexible start date between July and November of 2014. The fellow will work on a full-time basis at the FDA headquarters. For more details, please visit the Alzheimer’s Disease Regulatory Science Fellowshipdisclaimer icon webpage.